Custom iPSC-derived T Cell Service

Creative Biolabs is able to provide state-of-art custom services for any inducible pluripotent stem cell (iPSC)-derived T cells project with qualitative measurements. Our scientists specialized in stem cell therapy studies will work with you to develop a most appropriate strategy that will offer the most meaningful data for your research. We guarantee the finest results for our customers all over the world.

Introduction of iPSC-derived T Cell

iPSC technology has provided a new opportunity for generating a number of cell products applied in cell immunotherapy. Previous studies have illustrated that iPSCs can constantly produce T lymphocytes and can be easily cultured in vitro to trigger immune responses. Meanwhile, genetic engineering of iPSCs-derived T cells can emerge specific properties into the development of cell therapy to treat plenty of malignant diseases, such as tumors. Furthermore, recent researchers have revealed that T cells derived from iPSCs play an important role in maintaining the structural stability of T cell receptors (TCRs) during in vitro differentiation. As a result, iPSCs-derived T cells with the desired characteristics can be broadly used for generating therapeutic T cells in disease treatment. For example, iPSCs-derived T cells are capable of recognizing tumor antigens, including LMP2, WT-1, and MART-1, preventing the TCR rearrangement and keeping the antigen specificity in the cell therapy process.

Fig.1 Custom iPSC-derived T Cell Services.

Custom iPSC-derived T Cell Service

The potential role of iPSCs in cell therapy has been proved in the past few years. Up to now, iPSCs have become a valuable source of iPSC-derived T cells in treating a wide variety of human diseases, especially for various cancers. Therefore, Creative Biolabs has developed a series of custom assays to generate different iPSC-derived T cells, and identified their phenotypes or functions in xenograft models. For the differentiation methods, we have established detailed protocols to describe the process of iPSC-derived T cell development. In general, iPSCs are commonly induced to form mesoderm and then to produce hemogenic endothelium. Hemogenic endothelium further differentiates into hematopoietic stem and progenitor cells (HSPC). The final step is to obtain and test the functionality of mature CD8 or CD4 SP T cells. In addition, in order to avoid alloreactivity of iPSC-derived T cells, we have equipped with many advanced technologies for assessing TCR genetic modifications in the iPSCs.

Fig.2 Generation of iPSC-derived off-the-shelf tumor-specific T cells. ¹

Our service leverages the power of iPSCs to differentiate them into functional T cells, providing researchers with a renewable and scalable source of T cells for various applications.

Here is an overview of the process involved in our custom iPSC-derived T cell service:

• iPSC Generation: We start by generating iPSCs from various cell sources.
• T Cell Differentiation: The iPSCs are then differentiated into T cells through a series of carefully optimized protocols.
• Customization: Researchers have the option to customize their iPSC-derived T cells by introducing specific genetic modifications, such as TCR engineering or gene knockout, to tailor their functions for specific research needs.
• Quality Control: Throughout the process, we perform rigorous quality control assessments to ensure the purity, functionality, and stability of the iPSC-derived T cells, including flow cytometry analysis, TCR repertoire profiling, and functional assays.
• Delivery: Once the custom iPSC-derived T cells have passed all quality control checks, they are delivered to researchers in a cryopreserved format, ready for immediate use in downstream applications.

Our service provides researchers with a reliable and customizable platform to generate high-quality T cells for a wide range of applications in biotechnology research.

Why Creative Biolabs?

As a well-established company in the bio-industry, we offer custom stem cell therapy services based on iPSC technology. Guaranteed to perform project within the specified time frame, and the quality of iPSC-derived T cell product is always maintained to the end. Other features:

• Precise iPSC-derived T cell generation
• Specific functional profiles for iPSC-derived T cells
• Professional knowledge of stem cell therapy development
• Integrated solution based on multiple methods
• Cost-effective service manners

By focusing on quality, scientific expertise, flexibility, and responsiveness, Creative Biolabs is dedicated to providing a flexible and expedient iPSC-derived T cell solutions to meet global regulatory standards. Experienced teams of researchers and technicians have enabled our company to undertake any research with the highest standards and solid knowledge that span a wide range of stem cell therapy development and therapeutic areas. For additional details on our iPSC-based cell therapy services, please for free to contact us or send us an inquiry.

Published Data

Below are the findings presented in the article related to ipsc-derived T cells.

Sakiko Harada et al. generated dual antigen receptor (DR) T cells from iPSC to attenuate tumor antigen escape. These cells were modified to express a chimeric antigen receptor (CAR) directed against antigenic cell surface latent membrane protein 1 (LMP1) and a T-cell receptor directed against cell surface latent membrane protein 2 (LMP2), which binds to human leukocyte antigen A24 for the treatment of treatment-naïve Epstein-Barr virus-associated lymphoma.

In their study, they demonstrated that the constructed iPSC-derived DR T cells could recognize LMP1 antigen via CAR and LMP2 antigen via natural TCR. In treatment, these cells were superior to peripheral blood-derived LMP1-CART. They showed 100% survival and potently eliminated ENKL not only once. They also generated cells that recognized CD19 antigen via CAR and LMP2 antigen via the natural TCR to confirm reproducibility of results. Both types of iPSC-derived T cells had potent and long-lasting effects on EBV-driven tumors.

Fig. 3 Cytotoxicity of iPSC-derived T cells against EBV-associated lymphomas.²

FAQs

• Q: What level of customization can you provide in terms of cell surface markers and T cell subtypes?
  A: Our service offers high levels of customization for iPSC-derived T cells, including the expression of specific cell surface markers and differentiation into distinct T cell subtypes (e.g., CD4+ helper T cells, CD8+ cytotoxic T cells, regulatory T cells). We can also customize the expression of co-stimulatory molecules, activation markers, and other relevant proteins. Whether you need a specific phenotype for your experiments or want to study a particular T cell subset, we can tailor the cells to meet your requirements.
• Q: How scalable is your service for producing large quantities of iPSC-derived T cells for high-throughput screening?
  A: Our platform is designed for scalability, enabling the production of large quantities of iPSC-derived T cells suitable for high-throughput screening and other large-scale studies. We can produce batches ranging from small research-scale quantities to larger, industrial-scale quantities depending on your needs. We also ensure that batch-to-batch consistency is maintained, which is critical for reliable data in high-throughput applications.
• Q: What types of support do you provide post-delivery?
  A: We offer extensive post-delivery support to ensure the success of your project. Our scientific team is available for consultations to discuss experimental protocols, optimization strategies, and troubleshooting if needed. We provide detailed user guides with each cell batch, and if any issues arise, our experts are readily available to help resolve them. Additionally, we can offer follow-up services such as assay development and data analysis to further support your research.
• Q: Can your service be integrated with CRISPR/Cas9 gene editing to create knock-in or knock-out models using iPSC-derived T cells?
  A: Absolutely. We offer CRISPR/Cas9-based gene editing as part of our customization services. This allows us to generate knock-in or knock-out iPSC lines that can then be differentiated into T cells. Whether you are studying the role of a specific gene in T cell function or developing gene-edited models for therapeutic research, our team has the expertise to execute these modifications precisely.
• Q: What types of functional assays can you perform on iPSC-derived T cells to validate their activity?
  A: We offer a comprehensive suite of functional assays to validate the activity of iPSC-derived T cells. These assays include cytotoxicity tests to measure target cell killing, cytokine release assays, proliferation assays in response to antigen stimulation, and flow cytometry analysis for T cell markers and activation states. We can also perform specific assays tailored to your research objectives, such as TCR or CAR functionality tests.

Scientific Resources

iPSC Differentiation

iPSC for Cell Therapy

Learn More

References

1. Nianias, Alexandros, and Maria Themeli. "Induced pluripotent stem cell (iPSC)–derived lymphocytes for adoptive cell immunotherapy: recent advances and challenges." Current hematologic malignancy reports 14 (2019): 261-268.
2. Harada, Sakiko, et al. "Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma." Molecular Therapy 30.2 (2022): 534-549.

For Research Use Only. Not For Clinical Use.